CDE Launches Fast-Track IND Pilot for Gene Therapies in China — Key Takeaways for Foreign Biotechs
On April 1, 2025, the Center for Drug Evaluation (CDE, 国家药品监督管理局药品审评中心, Guójiā Yàopǐn Jiāndū Guǎnlǐ Jú Yàopǐn Shěnpíng Zhōngxīn) under China’s National Medical Products Administration (NMPA) launched a fast-track Investigational New Drug (IND) pilot program specifically for gene therapies, capping the first cohort at just 10 applications. This pilot slashes the standard IND review timeline from 12–18 months to a target of 60 working days — a potential reduction of up to 75% — aiming to accelerate clinical entry for cutting-edge gene therapies in a market projected to reach ¥67 billion by 2028.
What the Fast-Track IND Pilot Actually Changes
The CDE’s pilot is not a blanket speed-up. It targets gene therapy products (基因治疗产品, jīyīn zhìliáo chǎnpǐn) — defined as drugs that modify or manipulate gene expression through vector-delivered nucleic acids, including adeno-associated virus (AAV)-based, lentiviral, CRISPR-edited, and CAR-T therapies. Excluded are plasmid-only constructs and conventional biologics with incidental genetic components.
Under the standard IND route, a gene therapy application submits to a three-stage review: (1) administrative pre-check (5–10 days), (2) technical review by CDE (80 working days), and (3) supplementary queries and approval issuance (additional 2–4 months). The fast-track pilot compresses stages 2 and 3 into a single 60-working-day clock, with a dedicated review panel and a single round of written queries, after which the applicant has 5 working days to respond or the application is deemed withdrawn. The cost to the applicant: zero direct fees — the pilot charges the same ¥20,000 application fee as the standard route — but the compressed timeline demands a fully complete dossier at submission.
Timeline and Approval Reality: Before vs. After the Pilot
To understand the magnitude of the change, consider the historical baseline. Between 2020 and 2024, the average CDE IND approval for a gene therapy took 14.3 months, with the fastest approved CAR-T product (a domestic candidate) clearing in 9 months and the slowest AAV-based therapy taking 22 months due to multiple rounds of supplementary data requests. Meanwhile, in the US, the FDA’s median IND review for gene therapies in 2024 was 45 days for standard review and 22 days for fast-track or breakthrough designations — a stark contrast that has driven many Chinese biotechs to file IND-first in the US and delay China entry by 12–18 months.
The pilot aims to close that gap. The target 60 working days (~3 calendar months) is still longer than the FDA’s 22-day fast-track, but it represents a 5× improvement over China’s historical 14-month average. For foreign biotechs considering a 外商独资企业 (WFOE, wàishāng dúzī qǐyè) structure for clinical development in China, this compressed timeline can mean shaving a full year off the pre-revenue cash burn — a critical factor given that gene therapy startups typically require $50–100 million to reach Phase II proof-of-concept.
| Metric | Standard Route (2020–2024 Avg.) | Fast-Track Pilot (Target) | FDA Fast-Track (2024 Avg.) |
|---|---|---|---|
| Total review duration | 14.3 months | 60 working days (~3 months) | 22 calendar days |
| Quota per year | Unlimited | 10 applications | Unlimited |
| Supplementary query rounds | 2–4 rounds | 1 round max | 0–1 round |
| Approval rate | 62% | Not yet measured | ~85% with pre-IND meeting |
| Data acceptance flexibility | Moderate (accepts foreign bridging data with caveats) | Stringent (full package required at submission) | Flexible (accepts incremental data from ex-US sites) |
Source: CDE Annual Reports 2020–2024, NMPA policy document No. 2025-014, FDA CDER Fast-Track Data 2024.
Eligibility, Selection Criteria, and the Application Process
Not every gene therapy IND can apply. The CDE has set five hard eligibility criteria: (1) the product must be a first-in-human or first-in-China gene therapy with no prior IND approval anywhere; (2) the target indication must be a serious, life-threatening, or rare disease with no satisfactory therapy in China; (3) the applicant must have a demonstrated manufacturing facility for the vector or cell product — either in China or under a validated contract manufacturing organization (CMO) with an inspected facility; (4) the preclinical data package must include at least 6-month toxicology in two species (one rodent, one non-rodent) with biodistribution and shedding data; and (5) the applicant must agree to post-marketing commitment for long-term follow-up of 5–15 years depending on vector type.
Applications are accepted in two windows: May 1–15 and October 1–15, 2025. The CDE selects the 10 participants based on a scorecard weighting: novelty (30%), unmet need severity (30%), data completeness (25%), and manufacturing readiness (15%). Foreign applicants are explicitly eligible, but they must designate a China-based agent (local representative or subsidiary) for regulatory communications — a requirement that incentivizes the establishment of a WFOE or a joint venture with a local partner.
The process works as follows:
- Pre-IND meeting request filed with CDE at least 60 days before the application window. This is not mandatory but is strongly advised — 90% of approved INDs in 2024 held a pre-IND meeting.
- Dossier submission via the CDE’s electronic submission portal (eCTD format, Module 1–5 including the full clinical protocol and investigator’s brochure).
- CDE fast-track panel review (60 working days). The panel can request one round of written clarification, which the applicant must answer within 5 working days.
- Decision: approval (with or without conditions), clinical hold (with specific deficiencies), or rejection. Historical CDE data shows that 62% of gene therapy INDs are approved in the first cycle, 25% receive a clinical hold, and 13% are rejected outright.
What This Means for Foreign Biotech Companies Entering China
For foreign executives evaluating China entry for a gene therapy asset, the pilot creates a strategic bifurcation. If your asset meets the fast-track criteria and you have a complete preclinical package that satisfies CDE’s specific requirements (including Chinese population bridging data for pharmacokinetics and immunogenicity), you can realistically target IND approval in China within 3–4 months — versus the historical 12–18 months. This changes the calculus for parallel IND filings: rather than filing in the US and waiting a year to file in China, you can file in both jurisdictions nearly simultaneously, with China potentially lagging by only 2–3 months.
However, the pilot’s quota of 10 means fierce competition. Based on the CDE’s internal data, between January 2024 and March 2025, there were 37 gene therapy IND applications submitted — a run rate that would imply approximately 50 eligible candidates competing for 10 slots in 2025. The selection scoring places a premium on first-in-class mechanisms and rare diseases with no China therapy, favoring small biotechs with novel targets over me-too CAR-T programs at big pharmas.
For assets that do not qualify for the pilot — such as gene therapies for common diseases, products that already have IND approval elsewhere, or those with incomplete toxicology packages — the standard 12–18 month timeline still applies. Those companies should consider either accelerating their preclinical data generation to target a 2026 pilot window or pursuing a local partner with existing CDE regulatory infrastructure to reduce timeline friction.
Decision Framework: Pilot Eligibility and Strategy
If your gene therapy is first-in-human or first-in-China, targets a serious or rare disease with no China therapy, and you have a 6-month two-species toxicology package ready, apply for the fast-track pilot in the May or October 2025 window. The compressed timeline will offset the cost of setting up a WFOE or China agent.
If your asset has a prior IND approval in the US or another jurisdiction, targets a non-rare indication, or lacks the toxicology package, do not apply for the pilot — your application will be rejected early in the selection process. Instead, file through the standard route while using a pre-IND meeting to optimize your data package and reduce the risk of multiple supplementary rounds.
Three Pitfalls to Avoid in the Fast-Track Application
Cost: ¥3–8 million in resubmission fees (refiling as a standard IND after rejection) plus 12 months of timeline delay.
Fix: Conduct a pre-submission CMC audit against CDE’s 2024 Technical Guidelines for Gene Therapy Products (No. 2024-087) at least 90 days before the application window, and hold a pre-IND meeting to confirm CMC completeness with the CDE review team.
Cost: ¥1.5–4 million in additional studies (small bridging PK/PD in Chinese volunteers) plus 6–9 months of delay if the CDE places the IND on clinical hold.
Fix: Include a dedicated East Asian bridging analysis in your preclinical package, using either literature data on Chinese biomarker distributions or a small (n=20–30) healthy volunteer study conducted at a Chinese Phase I unit.
Cost: ¥0–500,000 in unplanned CRO or investigator fees during the pause, plus the opportunity cost of delayed clinical site activation.
Fix: Prepare pre-written responses for the five most common CDE queries on gene therapy INDs (dosing rationale, patient selection, vector biodistribution, shedding monitoring, and manufacturing consistency) before the review period begins. Assign a dedicated regulatory lead to respond within 3 working days of receiving a query.
Looking Ahead: What the Pilot Signals for Biotech in China
The fast-track gene therapy IND pilot is the most targeted regulatory acceleration China has attempted for a specific modality since the 2017–2018 pilot for innovative drug IND approvals (which covered small molecules and antibodies and eventually became permanent in 2020). The CDE’s decision to limit the pilot to 10 applications suggests a controlled experiment: if the cohort yields high-quality INDs with fast clinical enrollment and no safety surprises, the program may expand to a rolling quarterly quota of 20–30 applications by 2027. Conversely, if even one fast-tracked IND shows a serious adverse event traceable to regulatory oversights, the program may be delayed or restricted to domestic-only applicants.
For foreign biotechs, the pilot’s existence — even at the limited quota — signals that the CDE is serious about competing for global gene therapy innovation. The NMPA’s 2024–2028 five-year plan explicitly targets gene therapy as one of six “breakthrough modalities” for which it aims to achieve global regulatory convergence. This means that IND procedures, clinical trial requirements, and manufacturing standards for gene therapies in China will increasingly mirror those of the FDA and EMA — reducing the burden of duplicative requirements for companies that already have US or European clinical data.
The pilot also creates a first-mover advantage: the 10 companies that clear the fast-track IND in 2025 will have a 6–12 month head start over competitors who stay on the standard route, in a market where the first gene therapy to launch for a given indication typically captures 50–65% of the addressable patient pool. For a gene therapy targeting, say, hemophilia A (estimated 45,000 diagnosed patients in China), the revenue differential from a 12-month launch delay could exceed ¥1.2 billion in peak-year sales — dwarfing the ¥20,000 application fee.
NEXT STEPS for Foreign Biotech Executives
- Assess your asset’s pilot eligibility now. Use the CDE’s five criteria checklist (first-in-human or first-in-China, serious/rare disease, manufacturing facility qualification, 6-month toxicology, post-marketing commitment) to determine if your gene therapy qualifies for the May or October 2025 application window. Read our full guide on CDE Gene Therapy IND Package Requirements.
- Conduct a pre-IND regulatory gap analysis. The CDE’s technology requirements for gene therapies differ from FDA guidance in at least three specific areas — vector shedding monitoring duration, potency assay acceptance criteria, and Chinese population PK bridging — that commonly trip up foreign applicants. Use our Regulatory Compliance Checklist for China IND Filings to identify gaps before the 90-day pre-submission audit window closes.
- Select a China regulatory agent and qualified CRO. The CDE requires all foreign applicants to designate a China-based agent for fast-track communications, and the compressed 60-working-day timeline leaves no room for translation or coordination delays. Identify and contract with a CRO that has at least two prior gene therapy IND submissions to the CDE. See our guide on Choosing a CRO in China for Biotech Trials for selection criteria and comparison of the top five gene-therapy-experienced CROs in Shanghai, Beijing, and Suzhou.
— China Gateway 360 —
Remote China market entry support, built around execution.
